In a nutshell This study evaluated the effectiveness of 2 cm versus 4 cm excision margins for patients with thick melanomas on the surface of the skin (cutaneous). This study concluded that a 2-cm excision margin was safe for these patients. Some background The primary treatment for all stages of melanoma is surgery to remove the tumor. This involves...
Read More
In a nutshell This study investigated if nivolumab (Opdivo) is safe and effective in patients with rare melanoma subtypes (RMS) who progressed after ipilimumab (Yervoy). They found that this treatment was safe and improved survival in certain RMS. Some background Melanoma the most common cancers. There are many subtypes...
Read More
In a nutshell This study compared the long-term outcomes of two targeted therapies for patients with advanced melanoma. This study concluded that pembrolizumab (Keytruda) was more effective than ipilimumab (Yervoy) for these patients, with a similar rate of side effects. Some background Advanced melanoma is a type of skin cancer...
Read More
In a nutshell This trial is examining if adding antibody drug rituximab (Rituxan) and enzyme drug hyaluronidase human (Hycela) can increase the effectiveness of the standard treatment for melanoma. The main outcomes of this trial will be to examine the side effects experienced by patients and tumor response. This study is recruiting in...
Read More
In a nutshell This study investigated atezolizumab (Tecentriq) in combination with cobimetinib (Cotellic) and vemurafenib (Zelboraf) in BRAF-mutated melanoma. They found that this combination is promising and well tolerated in these patients. Some background Melanoma or skin cancer is often by...
Read More
In a nutshell This study investigated the effect of combined dabrafenib (Tafinlar), trametinib (Mekinist) and pembrolizumab (Keytruda) in melanoma. They found that this combination improved survival in advanced melanoma. Some background Melanoma or skin cancer is a common cancer. Genetic mutations can lead to...
Read More
In a nutshell This phase 1 trial is examining the effectiveness of personalized tumor antigens (PTA) in the treatment of different advanced tumors. The main outcomes to be measured will be side effects and disease control. This study is being conducted in Arizona, California, Louisiana and New Jersey, US. The details While the tumor cells are growing,...
Read MoreIn a nutshell This phase 1b/2 trial will investigate the safety of RMC-4630 and cobimetinib (Cotellic) in relapsed or unresponsive solid tumors. The main outcomes will be the number of side effects and the overall response rate. This trial is recruiting in a number of US states. The details Relapsed/refractory...
Read MoreIn a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced melanoma. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details Melanoma or skin cancer is one of the most common cancers. The...
Read MoreIn a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced melanoma. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details Melanoma or skin cancer is one of the most common cancers. The...
Read More
In a nutshell This study investigated female fertility preservation (FFP) in cancer patients. They found that FFP should be discussed with all women of reproductive age undergoing cancer treatment. Some background Cancer can have many negative effects on patient health. Infertility is a particular concern for younger female patients....
Read MoreIn a nutshell This trial aims to investigate adding tocilizumab (Actemra) to treatment with ipilimumab (Yervoy) and nivolumab (Opdivo) for patients with advanced melanoma. The main outcome that will be measured is how the tumor size changes. The study is being conducted in New York, United States. The details...
Read More
